Amarin Corporation/$AMRN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Amarin Corporation
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
Ticker
$AMRN
Sector
Primary listing
Employees
-
Headquarters
Dublin, Ireland
Website
AMRN Metrics
BasicAdvanced
$302M
-
-$5.02
0.78
-
Price and volume
Market cap
$302M
Beta
0.78
52-week high
$17.49
52-week low
$8.32
Average daily volume
59K
Financial strength
Current ratio
3.263
Quick ratio
2.247
Long term debt to equity
1.578
Total debt to equity
1.578
Interest coverage (TTM)
-7,314.14%
Profitability
EBITDA (TTM)
-48.25
Gross margin (TTM)
54.10%
Net profit margin (TTM)
-47.22%
Operating margin (TTM)
-23.34%
Effective tax rate (TTM)
-5.15%
Management effectiveness
Return on assets (TTM)
-4.35%
Return on equity (TTM)
-20.38%
Valuation
Price to revenue (TTM)
1.373
Price to book
0.65
Price to tangible book (TTM)
0.67
Price to free cash flow (TTM)
-26.143
Free cash flow yield (TTM)
-3.83%
Free cash flow per share (TTM)
-0.558
Growth
Revenue change (TTM)
-17.15%
Earnings per share change (TTM)
179.30%
3-year revenue growth (CAGR)
-22.74%
10-year revenue growth (CAGR)
13.06%
3-year earnings per share growth (CAGR)
-1.22%
10-year earnings per share growth (CAGR)
-11.19%
Bulls say / Bears say
The exclusive long-term licensing and supply agreement with Recordati secures a $25 million upfront payment and potential $150 million in milestone payments, providing significant non-dilutive funding and accelerating VAZKEPA’s commercialization in 59 European markets (Nasdaq).
Amarin ended Q2 2025 with $298.7 million in cash and no debt, ensuring ample liquidity to support operations, fund growth initiatives, and weather ongoing market challenges (Nasdaq).
European revenue in Q1 2025 surged to $5.4 million from $1.9 million a year earlier, highlighting robust ex-U.S. demand and early momentum for VAZKEPA in core markets such as Spain and the UK (Nasdaq).
U.S. net product revenue declined 17% year-over-year in Q2 2025 to $36.5 million amid intensified generic competition, undermining the company’s core U.S. cash flow generator (Nasdaq).
Amarin posted a net loss of $14.1 million, or $0.03 per ADS, in Q2 2025 versus net income of $1.5 million in Q2 2024, reflecting ongoing profitability challenges (Amarin).
The recognition of $22.8 million in restructuring charges in Q2 2025 to streamline global operations introduces execution risk and places short-term pressure on operating results (Amarin).
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Amarin Corporation stock?
Amarin Corporation (AMRN) has a market cap of $302M as of September 19, 2025.
What is the P/E ratio for Amarin Corporation stock?
The price to earnings (P/E) ratio for Amarin Corporation (AMRN) stock is 0 as of September 19, 2025.
Does Amarin Corporation stock pay dividends?
No, Amarin Corporation (AMRN) stock does not pay dividends to its shareholders as of September 19, 2025.
When is the next Amarin Corporation dividend payment date?
Amarin Corporation (AMRN) stock does not pay dividends to its shareholders.
What is the beta indicator for Amarin Corporation?
Amarin Corporation (AMRN) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.